A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Recruiting
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (K... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +191 locations
Conditions: Colorectal Neoplasms
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
Recruiting
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of California Irvine - Gavin Herbert Eye Institute, Irvine, California +9 locations
Conditions: Corneal Transplant Failure
Shoulder Innovations Clinical Data Registry
Recruiting
The goal of this multi-center observational study is to collect long-term clinical outcome information for anatomic and reverse total shoulder arthroplasty (shoulder replacement).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: California Pacific Orthopaedics, San Francisco, California +3 locations
Conditions: Shoulder Arthroplasty
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Recruiting
This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: BioResearch Partners Aventura, Aventura, Florida +2 locations
Conditions: Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Recruiting
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
07/17/2025
Locations: Diablo Clinical Research, Walnut Creek, California +12 locations
Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
Recruiting
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/17/2025
Locations: UAB Huntsville Regional Medical Campus, Huntsville, Alabama +36 locations
Conditions: Depressive Disorder, Major
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)
Recruiting
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +33 locations
Conditions: Leukemia, Myeloid, Acute
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Medical Dermatology Specialists, Phoenix, Arizona +39 locations
Conditions: Psoriasis, Overweight or Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona +56 locations
Conditions: Psoriatic Arthritis, Overweight or Obesity
PET [89Zr]DFO-starPEG in Solid Tumors
Recruiting
This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Solid Tumor, Solid Carcinoma, Soft Tissue Lesion
Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department
Recruiting
The goal of this proposal is to improve the quality and value of care for patients with acute chest pain by investigating the potential impact of point-of-care (POC) high sensitivity cardiac troponin (hs-cTn) testing in the Emergency Department (ED) and exploring how best to integrate POC hs-cTnl into ED risk stratification workflows. The study hypothesizes that the Abbott i-STAT POC hs-cTnI assay will decrease time-to-result (TTR) and ED length of stay (LOS), while increasing ED revenue for pat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Carolinas Medical Center, Charlotte, North Carolina +2 locations
Conditions: ACS (Acute Coronary Syndrome)
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
Recruiting
The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can help prevent the cancer from coming back in patients who are ctDNA-positive or who have evidence of cancer after treatment and surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Miami, Miami, Florida
Conditions: Non Small Cell Lung Cancer